Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • flibanserin
FDA Advances Treatment for Hypoactive Sexual Desire Disorder in Postmenopausal Women
Posted inWellness & Lifestyle

FDA Advances Treatment for Hypoactive Sexual Desire Disorder in Postmenopausal Women

Posted by By MedXY 07/29/2025
The FDA grants Priority Review to expand flibanserin use for treating low sexual desire in postmenopausal women, addressing an important gap in women's health.
Read More
  • Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial
  • Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial
  • Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia
  • Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
  • Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer clinical trial clinical trials diabetes diagnosis diet exercise FDA FDA approval GLP-1 health healthcare HIV Hypertension immunotherapy lifestyle lifestyle intervention longevity maternal health men's health Menopause mental health nutrition obesity older adults PCOS Pediatrics Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke treatment type 2 diabetes walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top